Overview

First in Human Study of T3P-Y058-739 (T3P)

Status:
Not yet recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

This is a first in human, phase I/II open-label, dose-finding, safety, and proof-of-concept clinical trial of T3P-Y058-739, a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

T3 Pharmaceuticals AG

Treatments:

Pembrolizumab